Pl-VEGF165 clinical trials
How each study uses pl-VEGF165 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pl-VEGF165 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 8
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test pl-VEGF165, phase 3 first.
- Mar 2027The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical TrialPhase 3 · JSC NextGen
- May 2027The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.Phase 2/3 · JSC NextGen
- Oct 2027The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's LesionsPhase 2/3 · JSC NextGen
Studies
Open first, then newest update. How each study uses pl-VEGF165 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's LesionsRecruitingPhase 2/3JSC NextGenNCT07459790Written as Neovasculgen®
- The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.RecruitingPhase 2/3JSC NextGenNCT07391306Written as Neovasculgen®
- The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical TrialRecruitingPhase 3JSC NextGenNCT07391319Written as Neovasculgen®
- Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic FootCompletedNot applicableHuman Stem Cell Institute, RussiaNCT02538705Written as Neovasculgen
- Efficiency, Safety and Portability of NeovasculgenCompletedPhase 2/3Human Stem Cell Institute, RussiaNCT03068585Written as Neovasculgen (Cambiogeneplasmid)
- Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb IschemiaCompletedPhase 4Human Stem Cell Institute, RussiaNCT02369809Written as Neovasculgen®
- Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's PhenomenonStatus unknownPhase 1/2Human Stem Cell Institute, RussiaNCT02356809Written as Neovasculgen
- Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve InjuryStatus unknownPhase 1/2Human Stem Cell Institute, RussiaNCT02352649Written as Neovasculgen